Closo-carboranyl- and metallacarboranyl [1,2,3]triazolyl-decorated lapatinib-scaffold for cancer therapy combining tyrosine kinase inhibition and boron neutron capture therapy

One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a variety of cancers are initially susceptible to chemotherapy, they eventually deve...

Full description

Bibliographic Details

Main Author:	Couto, Marcos (author)
Other Authors:	Alamón, Catalina (author), García Melián, María Fernanda (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Nievas, S. (author), Pozzi, E. (author), Curotto, P. (author), Thorp, S. (author), Dagrosa, M. A. (author), Teixidor, Francesc (author), Viñas, Clara (author), Cerecetto, Hugo (author)
Format:	article
Language:	English
Published:	2020
Subjects:	Tyrosine kinase inhibitors Lapatinib [1,2,3]triazolyl linker Boron clusters In vitro BNCT effect
Online Access:	https://hdl.handle.net/20.500.12008/32294
Tags:	Add Tag No Tags, Be the first to tag this record!